{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:53:59Z","timestamp":1790801639098,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Ceftolozane\u2010tazobactam is a new \u03b2\u2010lactam\/\u03b2\u2010lactamase inhibitor combination approved by the U.S. Food and Drug Administration in 2019 for the treatment of hospital\u2010acquired and ventilator\u2010associated pneumonia. The combination is a particularly potent inhibitor of penicillin\u2010binding proteins with higher affinity than other \u03b2\u2010lactam agents. Persons with cystic fibrosis (pwCF) often harbour resistant Gram\u2010negative bacteria in the airways and need antibiotics to prevent declining lung function. To test whether the introduction of ceftolozane\u2010tazobactam in the period 2015\u20132020 led to a bacterial population level increase in cephalosporin resistance in a Danish <jats:italic>CF<\/jats:italic> population. <jats:italic>In vitro<\/jats:italic>, activity of ceftolozane\u2010tazobactam was evaluated by susceptibility testing of clinical <jats:italic>Pseudomonas aeruginosa<\/jats:italic> isolated from pwCF from January 1, 2015, to June 1, 2020. Six thousand three hundred thirty two isolates collected from 210 adult pwCF were included. Thirty pwCF were treated with ceftolozane\u2010tazobactam at least once. Ceftolozane\u2010tazobactam exposure did not increase cephalosporin resistance on an individual or population level. However, resistance to ceftolozane\u2010tazobactam was recorded despite no prior exposure in four pwCF. Compared to ceftazidime, ceftolozane\u2010tazobactam had a better <jats:italic>in vitro<\/jats:italic> activity on <jats:italic>P.\u2009aeruginosa<\/jats:italic>. The percentage of non\u2010mucoid <jats:italic>P.\u2009aeruginosa<\/jats:italic> isolates susceptible to ceftolozane\u2010tazobactam were higher or equal to 5 other \u03b2\u2010lactams. Ceftolozane\u2010tazobactam expands the armamentaria against <jats:italic>P.\u2009aeruginosa<\/jats:italic> with acceptable levels for a selection of drug resistance.<\/jats:p>","DOI":"10.1111\/apm.13331","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T19:59:43Z","timestamp":1686340783000},"page":"419-425","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antimicrobial resistance of <i>Pseudomonas aeruginosa<\/i> in a cystic fibrosis population after introduction of a novel cephalosporin\/\u03b2\u2010lactamase inhibitor combination"],"prefix":"10.1111","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2233-500X","authenticated-orcid":false,"given":"Terese L.","family":"Katzenstein","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-0155","authenticated-orcid":false,"given":"Daniel","family":"Faurholt\u2010Jepsen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1725-5312","authenticated-orcid":false,"given":"Tavs","family":"Qvist","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-7186","authenticated-orcid":false,"given":"Peter \u00d8strup","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology Rigshospitalet  Copenhagen Denmark"},{"name":"Costerton Biofilm Center, Department of Immunology and Microbiology University of Copenhagen Faculty of Health and Medical Sciences  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6434-4975","authenticated-orcid":false,"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0268-3717","authenticated-orcid":false,"given":"Helle Krogh","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology Rigshospitalet  Copenhagen Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"},{"name":"The Novo Nordisk Foundation Center for Biosustainability Technical University of Denmark  Kgs. Lyngby Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-0384","authenticated-orcid":false,"given":"Mette","family":"Kolpen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3"},{"key":"e_1_2_9_3_1","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"4","author":"Langton Hewer SC","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12915"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.08.014"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30972-y"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009112"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1843.2003.00461.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.01.012"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115204"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00591-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015593293"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.03.021"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02462-13"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02688-16"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1825"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.03.002"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.02.003"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23451-y"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01969-14"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00512-2020"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.10.024"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01217.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.05.002"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.04.012"},{"key":"e_1_2_9_29_1","unstructured":"Breakpoints. EC.https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_12.0_Breakpoint_Tables.pdf"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00122-5"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0327-x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn090"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11030419"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apm.13331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:54:23Z","timestamp":1692248063000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apm.13331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/apm.13331"],"URL":"https:\/\/doi.org\/10.1111\/apm.13331","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"2023-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}